[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Perez et al., 2013 - Google Patents

A view on EGFR-targeted therapies from the oncogene-addiction perspective

Perez et al., 2013

View HTML
Document ID
17473952609649174116
Author
Perez R
Crombet T
Leon J
Moreno E
Publication year
Publication venue
Frontiers in pharmacology

External Links

Snippet

Tumor cell growth and survival can often be impaired by inactivating a single oncogen–a phenomenon that has been called as “oncogene addiction.” It is in such scenarios that molecular targeted therapies may succeed. among known oncogenes, the epidermal growth …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Perez et al. A view on EGFR-targeted therapies from the oncogene-addiction perspective
Hoang et al. A review of soft-tissue sarcomas: translation of biological advances into treatment measures
Steeg Targeting metastasis
Chong et al. The quest to overcome resistance to EGFR-targeted therapies in cancer
Vermorken et al. Optimal treatment for recurrent/metastatic head and neck cancer
Bareschino et al. Erlotinib in cancer treatment
Viloria-Petit et al. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies
Zanardi et al. Better together: targeted combination therapies in breast cancer
Rivera et al. Cetuximab, its clinical use and future perspectives
Monk et al. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
Belani et al. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
Lyons et al. Systemic therapy for esophagogastric cancer: targeted therapies
Wheatley-Price et al. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes
Gadgeel Personalized therapy of non-small cell lung cancer (NSCLC)
Glynne-Jones et al. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers
Richards et al. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo
Aparo et al. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy
Ha et al. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma
Ishii et al. Dawn of precision medicine on gastric cancer
Wang et al. Pan-HER-targeted approach for cancer therapy: mechanisms, recent advances and clinical prospect
Kim et al. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
De Pauw et al. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer
Napolitano et al. Targeting the EGFR signalling pathway in metastatic colorectal cancer
Joseph et al. Targeted therapy: its status and promise in selected solid tumors: part II: impact on selected tumor subsets, and areas of evolving integration
Metro et al. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance